Stay updated on the most recent developments in Symeres.

  • Chiralix, a Symeres company

    At Symeres, many passionate scientists are engaged in R&D projects with […]

    Read more

  • C&ENs 10 Start-Ups to Watch

    This week, the 2021 Chemical & Engineering News list of ‘10 […]

    Read more

  • Expanding the toolbox: Resolving racemates

    Symeres has quite a legacy when it comes to university collaborations. […]

    Read more

  • From CRO client to CRO employee: An interview with Dr. Chris Teleha

    While working in big pharma, Dr. Chris Teleha spent years working with CROs […]

    Read more

  • On the road again: Experiencing BioTrinity 2021 as our first 2021 live event

    COVID-19 has changed how we interact with people and has forced […]

    Read more

  • The ‘Art of API’

    In their book, The Logic of Chemical Synthesis, E. J. Corey and Xue-Min […]

    Read more

  • Renewal of the GMP certificate for Symeres Prague

    This spring, Symeres Prague was audited by the national control authority […]

    Read more

  • Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer

    Earlier this year, our client TOLREMO therapeutics nominated the clinical candidate […]

    Read more

  • Symeres joins forces with Keensight Capital

    Paris (France) – May 25th 2021 We are pleased to let […]

    Read more

  • Excellent HTS hits by design, not by accident

    The identification of tractable chemical starting points in the drug discovery […]

    Read more

  • A follow-up on the European Lead Factory: The Symegold library

    Delivery of an innovative 80,000 compound lead-like library for HTS and […]

    Read more

Feel free to contact us!

Curious to know more about what can we do for you? Get in touch and let’s start a conversation.

Contact us